Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…
HOME > COLUMN
COLUMN
- Why Top-Tier Recruiters Must Embrace Their Creative Side
January 31, 2019
- Expat Truths from the Japanese Medical Device World
December 3, 2018
- Why Did the Project Take so Long?
November 16, 2018
- Finding Captains in Your Organization
October 12, 2018
- Riding the Trend: Staffing Pharma Startups in Japan
September 7, 2018
- How Having a Great CSR Program Can Help with Recruiting and Retaining Top Talent
August 16, 2018
- Rare Disease Pharmaceuticals in Japan to See New Demand for Skilled Human Resources
July 20, 2018
- 5 Billion Yen Blockbuster?
June 20, 2018
- It Is Thumbs Up for Cell Therapy in Japan
March 23, 2018
- Unique Opportunities at Pharmaceutical Companies Treating Rare Diseases
February 23, 2018
- When Leading Teams, Focus on the Principles, Not the Personalities
January 26, 2018
- What to Do about the Feeling of Torschlusspanik?
October 27, 2017
- Women! Rock the Boat and Get Promoted
September 22, 2017
- Getting the Right Message
August 25, 2017
- Putting on Your Pants
July 21, 2017
- Reputable Combination
July 11, 2017
- What Is the Best Path to Customers’ Hearts and Minds?
June 19, 2017
- Doubling Down on Digital
May 26, 2017
- Global Opportunities for Global Minds
April 21, 2017
- Will Tepid Pricing Debate Only Go Full-Throttle after Golden Week Holidays?
March 30, 2017
ページ
Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…
With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…
As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…